Incyte Corporation Company Profile (NASDAQ:INCY)

About Incyte Corporation (NASDAQ:INCY)

Incyte Corporation logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INCY
  • CUSIP: 45337C10
  • Web:
  • Market Cap: $24.94092 billion
  • Outstanding Shares: 210,650,000
Average Prices:
  • 50 Day Moving Avg: $126.44
  • 200 Day Moving Avg: $129.92
  • 52 Week Range: $83.01 - $153.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 316.46
  • P/E Growth: -1.27
Sales & Book Value:
  • Annual Revenue: $1.31 billion
  • Price / Sales: 18.83
  • Book Value: $4.99 per share
  • Price / Book: 23.46
  • EBIDTA: $9.84 million
  • Net Margins: -11.77%
  • Return on Equity: -21.57%
  • Return on Assets: -9.33%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 2.88%
  • Quick Ratio: 2.87%
  • Average Volume: 1.35 million shs.
  • Beta: 0.91
  • Short Ratio: 2.92

Frequently Asked Questions for Incyte Corporation (NASDAQ:INCY)

What is Incyte Corporation's stock symbol?

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte Corporation's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The business earned $326.40 million during the quarter, compared to analysts' expectations of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The firm's revenue for the quarter was up 32.5% on a year-over-year basis. During the same period last year, the company earned $0.18 EPS. View Incyte Corporation's Earnings History.

When will Incyte Corporation make its next earnings announcement?

Incyte Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Incyte Corporation.

Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?

22 analysts have issued 12 month target prices for Incyte Corporation's stock. Their predictions range from $115.00 to $174.00. On average, they anticipate Incyte Corporation's stock price to reach $143.55 in the next year. View Analyst Ratings for Incyte Corporation.

What are analysts saying about Incyte Corporation stock?

Here are some recent quotes from research analysts about Incyte Corporation stock:

  • 1. Cowen and Company analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 2. According to Zacks Investment Research, "Incyte’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations. The growth in Jakafi sales is driven by patient demand and should boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. This is owing to the larger potential patient population and the possibility for longer duration of treatment. The company exited the first quarter with approximately 10,000 patients being treated with Jakafi. However, Incyte’s dependence on a single product, Jakafi, for growth is concerning. Moreover, the FDA has issued a CRL to new drug application (NDA) for baricitinib asking for additional information. The delay in approval is disappointing. Moreover, loss estimates for 2017 have widened significantly following the first-quarter results." (5/23/2017)
  • 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)

Who are some of Incyte Corporation's key competitors?

Who are Incyte Corporation's key executives?

Incyte Corporation's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer
  • David W. Gryska, Chief Financial Officer, Executive Vice President
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer
  • Eric H. Siegel, Executive Vice President, General Counsel
  • Paula J. Swain, Executive Vice President - Human Resources
  • Barry P. Flannelly, Executive Vice President and General Manager , US
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development`
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry
  • Steven H. Stein M.D., Vice President and Chief Medical Officer
  • Julian C. Baker, Lead Independent Director

Who owns Incyte Corporation stock?

Incyte Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.33%), State Street Corp (3.65%), Capital World Investors (3.30%), Capital International Investors (3.11%), BB Biotech AG (1.71%) and Franklin Resources Inc. (1.47%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte Corporation.

Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including Capital Guardian Trust Co., Bank of New York Mellon Corp, FMR LLC, Capital World Investors, Canada Pension Plan Investment Board, Fred Alger Management Inc., Victory Capital Management Inc. and Cibc World Markets Corp. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?

Incyte Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Janus Henderson Group PLC, Jennison Associates LLC, Matrix Capital Management Company LP, Capital International Investors, Balyasny Asset Management LLC, Eagle Asset Management Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have bought Incyte Corporation stock in the last two years include Bros Advisors Lp Baker, Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

How do I buy Incyte Corporation stock?

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte Corporation's stock price today?

One share of Incyte Corporation stock can currently be purchased for approximately $117.09.

MarketBeat Community Rating for Incyte Corporation (NASDAQ INCY)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  815 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  1,066
MarketBeat's community ratings are surveys of what our community members think about Incyte Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Incyte Corporation (NASDAQ:INCY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $143.55 (22.60% upside)

Analysts' Ratings History for Incyte Corporation (NASDAQ:INCY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$136.00LowView Rating Details
9/13/2017ArgusReiterated RatingBuy$150.00LowView Rating Details
9/10/2017Oppenheimer Holdings, Inc.Reiterated RatingHold$135.00LowView Rating Details
9/11/2017BMO Capital MarketsReiterated RatingOutperform$172.00 -> $163.00LowView Rating Details
9/11/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$159.00HighView Rating Details
8/31/2017J P Morgan Chase & CoReiterated RatingBuy$149.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$135.00MediumView Rating Details
8/2/2017Barclays PLCReiterated RatingOverweight$180.00 -> $165.00LowView Rating Details
7/27/2017Jefferies Group LLCReiterated RatingBuy$148.00MediumView Rating Details
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00LowView Rating Details
7/3/2017Cowen and CompanyReiterated RatingOutperform$130.00MediumView Rating Details
6/28/2017GabelliReiterated RatingBuy$174.00MediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust Banks, Inc.Lower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/18/2017Goldman Sachs Group, Inc. (The)Lower Price TargetBuy$149.00 -> $136.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of America CorporationReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Incyte Corporation (NASDAQ:INCY)
Earnings by Quarter for Incyte Corporation (NASDAQ:INCY)
Earnings History by Quarter for Incyte Corporation (NASDAQ INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017($0.05)($0.06)$318.45 million$326.40 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corporation (NASDAQ:INCY)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20176($0.08)$0.32$0.06
Q4 20176($0.06)$0.22$0.08
Q2 20191$0.65$0.65$0.65
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corporation (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Incyte Corporation (NASDAQ:INCY)
Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 88.91%
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Barry P FlannellyEVPSell714$124.25$88,714.50View SEC Filing  
9/8/2017Bros. Advisors Lp BakerDirectorBuy100,000$132.00$13,200,000.00View SEC Filing  
9/5/2017Paul TrowerInsiderSell3,000$138.41$415,230.00View SEC Filing  
9/1/2017Eric H SiegelEVPSell1,820$137.40$250,068.00View SEC Filing  
8/31/2017Paula J SwainEVPSell20,000$140.00$2,800,000.00View SEC Filing  
8/29/2017Steven H SteinEVPSell2,111$125.00$263,875.00View SEC Filing  
8/4/2017Paul TrowerInsiderSell3,000$125.25$375,750.00View SEC Filing  
8/1/2017Eric H SiegelEVPSell1,820$132.92$241,914.40View SEC Filing  
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.65View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.00View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.00View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.26View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.00View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.60View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.00View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.00View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.00View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Incyte Corporation (NASDAQ:INCY)
Latest Headlines for Incyte Corporation (NASDAQ:INCY)
DateHeadline logoIncyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell - September 18 at 11:19 AM logoIncyte Corporation (INCY) Receives Consensus Rating of "Buy" from Analysts - September 16 at 3:20 PM logoInsider Selling: Incyte Corporation (INCY) EVP Sells 714 Shares of Stock - September 15 at 8:02 PM logoLilly and Incyte's baricitinib successful in mid-stage dermatitis study - Seeking Alpha - September 15 at 1:08 AM logoIncyte Corporation (INCY) Coverage Initiated by Analysts at Royal Bank Of Canada - September 14 at 5:26 PM logoGabelli Comments on Incyte Corporation's FY2020 Earnings (INCY) - September 13 at 4:02 PM logoIncyte Corporation (INCY) Rating Reiterated by Argus - September 13 at 12:26 PM logoIncyte Corporation (INCY) Expected to Post Quarterly Sales of $356.96 Million - September 12 at 2:00 AM logoIncyte (INCY) Reports Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with Merck ... - - September 12 at 1:33 AM logoIncyte Corporation (INCY) Presents At European Society for Medical Oncology Annual Congress - Slideshow - September 11 at 8:31 PM logo[$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances - September 11 at 8:30 PM logoIncyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017 - September 11 at 8:30 PM logoIncyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - September 11 at 8:30 PM logoBMO Capital Markets Reaffirms "Buy" Rating for Incyte Corporation (INCY) - September 11 at 3:50 PM logoOppenheimer Holdings, Inc. Reaffirms Hold Rating for Incyte Corporation (INCY) - September 11 at 3:12 PM logoIncyte Corporation (INCY) Upgraded at Raymond James Financial, Inc. - September 11 at 9:04 AM logoZacks: Brokerages Expect Incyte Corporation (INCY) Will Post Earnings of $0.02 Per Share - September 10 at 6:24 PM logoProgression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with KEYTRUDA - Business Wire (press release) - September 10 at 12:17 AM logoMarket Close Report: NASDAQ Composite index closes at 6360.19 down -37.68 points - Nasdaq - September 9 at 4:20 AM logoIncyte (INCY) Says It Priced 4.95M Common Stock Offering - September 8 at 11:16 PM logoBros. Advisors Lp Baker Purchases 100,000 Shares of Incyte Corporation (INCY) Stock - September 8 at 7:34 PM logoThe Hype for Immune-Oncology Drugs Is Still Too Hot - September 7 at 8:07 PM logoInsider Selling: Incyte Corporation (INCY) Insider Sells 3,000 Shares of Stock - September 7 at 7:42 PM logoThe Key Reason Incyte Corporation Added $850 Million in Market ... - Motley Fool - September 6 at 6:22 AM logoIncyte Corporation (INCY) EVP Sells $250,068.00 in Stock - September 5 at 8:06 PM logoIncyte Corporation (INCY) EVP Paula J. Swain Sells 20,000 Shares - September 5 at 7:23 PM logoBiotech Forum Daily Digest: Revisiting Progenics After Manufacturing Delay - September 4 at 6:44 PM logoIncyte Corporation (INCY) Given "Hold" Rating at Oppenheimer Holdings, Inc. - August 31 at 10:38 PM logoIncyte Corporation's (INCY) Buy Rating Reiterated at J P Morgan Chase & Co - August 31 at 8:56 PM logoLilly/Incyte to Re-File Baricitinib NDA Faster Than Expected - Nasdaq - August 31 at 7:52 PM logoSteven H. Stein Sells 2,111 Shares of Incyte Corporation (INCY) Stock - August 31 at 7:42 PM logoIncyte (INCY) Announces New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate ... - - August 31 at 6:14 AM logoIBD Rating Upgrades: Incyte Shows Improved Price Strength - August 30 at 1:28 AM logoBMO Capital Markets Reiterates "Outperform" Rating for Incyte Corporation (INCY) - August 28 at 9:36 AM logoCommit To Purchase Incyte Corporation At $100, Earn 9.7% Using Options - August 24 at 7:55 AM logoAssessing Incyte’s 2Q17 Revenue Growth - August 23 at 7:12 AM logoIncyte Corporation (INCY) Given Consensus Rating of "Buy" by Analysts - August 22 at 2:40 PM logoCURE® Magazine Seeks Nominations for 2017 MPN Heroes® Awards - Business Wire (press release) - August 19 at 12:42 AM logoIncyte Corporation 2017 Q2 - Results - Earnings Call Slides - August 18 at 7:40 PM logoCURE® Magazine Seeks Nominations for 2017 MPN Heroes® Awards - August 18 at 5:37 AM logoEvercore ISI Initiates Coverage on Incyte Corporation (INCY) - August 16 at 6:58 PM logoForbes Magazine Names Incyte One of the World's Most Innovative Companies for Third Consecutive Year - Business Wire (press release) - August 11 at 3:59 AM logoIHS Markit Score Update: Drop in demand for ETFs holding Incyte Corp is a negative sign for its shares - August 11 at 3:59 AM logoForbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year - August 11 at 3:59 AM logoCalithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2017 Results - Earnings Call Transcript - August 10 at 1:11 AM logoIncyte Corporation (NASDAQ:INCY) Insider Sells $375,750.00 in Stock - August 7 at 8:02 PM logo Analysts Expect Incyte Corporation (INCY) Will Announce Earnings of $0.05 Per Share - August 5 at 12:10 AM logoIncyte Corporation (NASDAQ:INCY) Downgraded by BidaskClub to "Hold" - August 4 at 11:52 PM logoFY2017 EPS Estimates for Incyte Corporation (NASDAQ:INCY) Decreased by Gabelli - August 4 at 11:08 AM logoFY2017 Earnings Estimate for Incyte Corporation Issued By William Blair (INCY) - August 4 at 11:08 AM



Incyte Corporation (INCY) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff